Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein

Recombinant factor IX Fc (rFIXFc) fusion protein is the first of a new class of bioengineered long-acting factors approved for the treatment and prevention of bleeding episodes in haemophilia B. The aim of this work was to describe the manufacturing process for rFIXFc, to assess product quality and...

Descripción completa

Detalles Bibliográficos
Autores principales: McCue, J, Osborne, D, Dumont, J, Peters, R, Mei, B, Pierce, G F, Kobayashi, K, Euwart, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282370/
https://www.ncbi.nlm.nih.gov/pubmed/24811361
http://dx.doi.org/10.1111/hae.12451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282370/
https://www.ncbi.nlm.nih.gov/pubmed/24811361
http://dx.doi.org/10.1111/hae.12451

Ejemplares similares